Recently, Hengrui Medicine received the Drug Registration Approval issued by the State Drug Administration and approved the company's Celecoxib capsules for sale.
Celecoxib is a non-steroidal anti-inflammatory drug that selectively inhibits COX-2. It is mainly used to relieve the symptoms and signs of osteoarthritis, adult rheumatoid arthritis and ankylosing spondylitis, and to treat acute pain in adults. The original research drug was approved by the US FDA in 1998 and is the world's first selective non-steroidal anti-inflammatory analgesic. It successfully solved the problem of gastrointestinal injury of traditional non-steroidal anti-inflammatory analgesics. Breakthrough. "
Hengrui Pharmaceutical Celecoxib Capsule submitted its registration application to the State Food and Drug Administration in July 2017, and was included in the priority review by the State Drug Administration in November 2017. Evaluation.
Among the hot drug Xibu products for clinical treatment of arthritis, in addition to the celecoxib capsules approved this time, Hengrui Medicine has already launched a self-developed Class 1 new drug, iRexibu, as early as 2011. In the future, Hengrui Medicine will further expand and improve the product pipeline layout. Based on independent innovation, independent research and development and high-end imitation will go hand in hand to promote high-end preparations to achieve import substitution, solve drug accessibility issues, and better benefit patients.